LPA and coronary artery disorder: We have shown that, in patients with early CHD manifestation, elevated levels of Lp(a), but not LMW apo(a) phenotype, increased the risk of cardiovascular events during long-term follow-up despite ongoing statin therapy and correction of modifiable risk factors.